Trial outcomes first
We optimize for better studies and stronger operating decisions, keeping the work tied to real trial outcomes instead of internal process theater.
Company
TrialStack helps clinical teams move from protocol design to submission-ready study packages through structured evidence review, document generation, and auditable start-up decisions aligned with ICH M11 and USDM.
We optimize for better studies and stronger operating decisions, keeping the work tied to real trial outcomes instead of internal process theater.
The operating record should stay visible, reviewable, and durable so decisions, rationale, and follow-through do not disappear into side channels.
People closest to the work should be able to move with judgment while the system keeps responsibilities, review paths, and ownership legible.
We prefer concrete execution, clear standards, and encoded learning so each engagement strengthens the product instead of creating bespoke drift.
2022
DCT supply and patient engagement sat too far downstream from the sponsor decisions that actually shape study quality and timelines.
2023
Patient insights and AI drafting were useful, but neither created a durable product edge or a strong standalone buying motion.
2024
The shift was treating protocol and study setup as structured definition instead of document production, with evidence and decisions built in.
2025
With structure in place, the product can extend into generation, alignment, deployment, and governed execution from one connected system.
TrialStack is built by a small founding team covering product direction, operating discipline, and market trust. Together they keep the company legible, the work grounded, and the product connected to real clinical operating needs.
Get started
Talk through your trial design, evidence review, document generation, and start-up workflows, then choose the Studio, Loop, or Catalyst path that fits your team.